Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Catalin Marian, Victor Babes University of Medicine and Pharmacy, Romania

*CORRESPONDENCE Tomasz Sirek I drtkierka@gmail.com

RECEIVED 17 February 2025 ACCEPTED 21 March 2025 PUBLISHED 08 April 2025

CITATION

Sirek T, Król-Jatręga K, Borawski P, Zmarzły N, Boroń D, Ossowski P, Nowotny-Czupryna O, Boroń K, Janiszewska-Bil D, Mitka-Krysiak E and Grabarek BO (2025) Corrigendum: Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets. *Front. Oncol.* 15:1558771. doi: 10.3389/fonc.2025.1558771

COPYRIGHT

© 2025 Sirek, Król-Jatręga, Borawski, Zmarzły, Boroń, Ossowski, Nowotny-Czupryna, Boroń, Janiszewska-Bil, Mitka-Krysiak and Grabarek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/ mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets

Tomasz Sirek^{1,2*}, Katarzyna Król-Jatręga^{1,2}, Przemysław Borawski³, Nikola Zmarzły⁴, Dariusz Boroń^{4,5,6,7}, Piotr Ossowski⁴, Olga Nowotny-Czupryna⁴, Kacper Boroń¹, Dominika Janiszewska-Bil⁴, Elżbieta Mitka-Krysiak⁴ and Beniamin Oskar Grabarek^{4,8}

¹Department of Plastic Surgery, Faculty of Medicine, Academia of Silesia, Katowice, Poland, ²Department of Plastic and Reconstructive Surgery, Hospital for Minimally Invasive and Reconstructive Surgery in Bielsko-Biała, Bielsko-Biała, Poland, ³Independent Researcher, Włocławek, Poland, ⁴Department of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland, ⁵Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Kraków, Poland, ⁶Department of Gynecology and Obstetrics, TOMMED Specjalisci od Zdrowia, Katowice, Poland, ⁷University of Economics and Humanities in Warsaw, Warszawa, Poland, ⁸Department of Molecular, Biology Gyncentrum Fertility Clinic, Katowice, Poland

KEYWORDS

breast cancer, miRNA, PI3K/Akt/mTOR pathway, molecular marker, mRNA

A Corrigendum on

Distinct mRNA expression profiles and miRNA regulators of the PI3K/ AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets

By Sirek T, Król-Jatręga K, Borawski P, Zmarzły N, Boroń D, Ossowski P, Nowotny-Czupryna O, Boroń K, Janiszewska-Bil D, Mitka-Krysiak E and Grabarek BO (2025). *Front. Oncol.* 14:1515387. doi: 10.3389/fonc.2024.1515387

In the published article, there was an error in Figure 1 as published. The incorrect image was displayed. The corrected Figure 1 and its caption "Venn diagram of genes differentiating breast cancer from the control. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; *COL1A1*, collagen type I alpha 1; COL1A2, collagen type I alpha 2; *COL2A1*, Collagen Type II Alpha 1 Chain; *COL4A1*, Collagen Type IV Alpha 1 Chain; *COL4A4*, Collagen Type IV Alpha 4 Chain; *COL4A6*, Collagen Type IV Alpha 6 Chain; *COL6A2*, Collagen Type VI Alpha 2 Chain; *PIK3CA*, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; *PIK3CD*, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; *PIK3CG*,

10.3389/fonc.2025.1558771

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; *PIK3R1*, Phosphoinositide-3-Kinase Regulatory Subunit 1; *PIK3R4*, Phosphoinositide-3-Kinase Regulatory Subunit 4; *MAPK1*, Mitogen-Activated Protein Kinase 1; *MAPK3*, Mitogen-Activated Protein Kinase 3; *MAP2K2*, Mitogen-Activated Protein Kinase Kinase 2; *mTOR*, Mechanistic Target of Rapamycin" appear below.

In the published article, there was an error in Figure 2 as published. The incorrect image was displayed. The corrected Figure 2 and its caption "Expression profile of selected genes determined by qRT-PCR. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triplenegative breast cancer; C, control; COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin" appear below.

In the published article, there was an error in Figure 3 as published. The incorrect image was displayed. The corrected Figure 3 and its caption "Relationship network for the selected PI3K/AKT/mTOR pathway differentiation genes generated in the STRING database. COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin" appear below.

In the published article, there was an error in Figure 6 as published. The incorrect image was displayed. The corrected Figure 6 and its caption "Overall survival analysis for luminal B HER2+ subtype" appear below.

In the published article, there was an error in Figure 7 as published. The incorrect image was displayed. The corrected Figure 7 and its caption "Overall survival analysis for nonluminal HER2+ cancers subtype" appear below.

In the published article, there was an error in Figure 8 as published. The incorrect image was displayed. The corrected Figure 8 and its caption "Overall survival analysis for TNBC subtype" appear below.

In the published article, there was an error. The title of subsection 3.1 was incorrect.

A correction has been made to **Section 3. Results**, *Sub-section 3.1*. This sentence previously stated:

"Microarray profile of histaminergic system-related genes breast cancer samples in comparison with control tissue"

The corrected sentence appears below:

"Microarray profile of PI3K/AKT/mTOR pathway-related genes breast cancer samples in comparison with control tissue"

In the published article, there was an error. The title of subsection 3.2 was incorrect.

A correction has been made to **Section 3. Results**, *Sub-section 3.2*. This sentence previously stated:

"Expression pattern of histaminergic system-related genes in breast cancer samples compared to control tissue analyzed by qRT-PCR"

The corrected sentence appears below:

"Expression pattern of PI3K/AKT/mTOR pathway-related genes in breast cancer samples compared to control tissue analyzed by qRT-PCR"

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



FIGURE 1

Venn diagram of genes differentiating breast cancer from the control. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; *COL1A1*, collagen type I alpha 1; COL1A2, collagen type I alpha 2; *COL2A1*, Collagen Type II Alpha 1 Chain; *COL4A4*, Collagen Type IV Alpha 4 Chain; *COL4A6*, Collagen Type IV Alpha 6 Chain; *COL6A2*, Collagen Type VI Alpha 2 Chain; *PIK3CA*, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; *PIK3CB*, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; *PIK3CG*, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit 1; *PIK3R4*, Phosphoinositide-3-Kinase Regulatory Subunit 1; *PIK3R4*, Phosphoinositide-3-Kinase Regulatory Subunit 1; *PIK3R4*, Phosphoinositide-3-Kinase Regulatory Subunit 1; *MAPK1*, Mitogen-Activated Protein Kinase 1; *MAPK3*, Mitogen-Activated Protein Kinase 3; *MAP2K2*, Mitogen-Activated Protein Kinase 2; *mTOR*, Mechanistic Target of Rapamycin.



Expression profile of selected genes determined by qRT-PCR. LumA, luminal A; LumB, luminal B; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; C, control; COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin.



FIGURE 3

Relationship network for the selected PI3K/AKT/mTOR pathway differentiation genes generated in the STRING database. COL1A1, collagen type I alpha 1; COL1A2, collagen type I alpha 2; COL2A1, Collagen Type II Alpha 1 Chain; COL4A1, Collagen Type IV Alpha 1 Chain; COL4A4, Collagen Type IV Alpha 4 Chain; COL4A6, Collagen Type IV Alpha 6 Chain; COL6A2, Collagen Type VI Alpha 2 Chain; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta; PIK3CD, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta; PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3R4, Phosphoinositide-3-Kinase Regulatory Subunit 4; MAPK1, Mitogen-Activated Protein Kinase 1; MAPK3, Mitogen-Activated Protein Kinase 3; MAP2K2, Mitogen-Activated Protein Kinase Kinase 2; mTOR, Mechanistic Target of Rapamycin.





